help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 44, No. 6 1197-1199
doi:10.1210/jcem-44-6-1197
Copyright © 1977 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TOLIS, G.
Right arrow Articles by NAFTOLIN, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TOLIS, G.
Right arrow Articles by NAFTOLIN, F.

Ineffectiveness of Pyridoxine (B6) to Alter Secretion of Growth Hormone and Prolactin and Absence of Therapeutic Effects on Galactorrhea-Amenorrhea Syndromes

G. TOLIS1, R. LALIBERTÈ2, H. GUYDA1 and F. NAFTOLIN2

1 Departments of Medicine, McGill University, Royal Victoria Hospital, Montreal, Canada
2 Departments of Obstetrics and Gynecology, McGill University, Royal Victoria Hospital Montreal, Canada

The acute effect of pyridoxine (B6) on serum GH and PRL levels and its chronic effects on galactorrhea in nine subjects (group I, n = 4, idiopathic galactorrhea with normal PRL levels and normal menses; Group II, n = 5, galactorrheaamenorrhea with increased PRL levels) have been studied. Pyridoxine did not acutely alter GH or PRL levels. There was no decrease in galactorrhea, no resumption of menses and no decrease in PRL following two months of B6 therapy. In contrast, bromocriptine was effective in suppressing galactorrhea and restoring normal menses in group II subjects and remains the therapy of choice for this purpose.

Supported by the Quebec Research Council G.T- 750101 and the Medical Research Council of Canada HG, MT-4403; FN MT-5823.

Received November 2, 1976.




This article has been cited by other articles:


Home page
EndocrinologyHome page
S.-G. Ren and S. Melmed
Pyridoxal Phosphate Inhibits Pituitary Cell Proliferation and Hormone Secretion
Endocrinology, August 1, 2006; 147(8): 3936 - 3942.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
A. G. Renwick
Toxicology of Micronutrients: Adverse Effects and Uncertainty
J. Nutr., February 1, 2006; 136(2): 493S - 501S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1977 by The Endocrine Society